Pleco Therapeutics works on a new way to treat cancer with the help of grants

Pleco Therapeutics is a biopharmaceutical company that develops medicines and an innovative technology for the treatment of cancer. This technology can improve the outlook for patients with acute myeloid leukaemia, a rare blood cancer. Small cell lung cancer, pancreatic cancer and neurological diseases such as Alzheimer’s and Parkinson’s also fall within its field of research.

Pleco Therapeutics viert deze zomer haar vijfjarig bestaan. De nog jonge onderneming werd opgericht door Ivo Timmermans. Hij studeerde geneeskunde aan de Radboud Universiteit in Nijmegen. Kort daarna werkte hij voor verschillende biofarmaceutische bedrijven, waar hij in aanraking kwam met geneesmiddelenonderzoek. Dat sprak Ivo direct aan. Na een carrière van 25 jaar binnen de reguliere farma deed zich een nieuwe uitdaging voor. “Ongeveer zes jaar geleden kwam ik contact met een oncoloog uit Houston. Zij had een interessante nieuwe manier om kanker te behandelen. Toen ik de mogelijkheid had, heb ik heb de stoute schoenen aangetrokken en ben ik naar Houston gegaan. Het academisch leukemie centrum waar zij voor werkt was op zoek naar een commerciële partner om het product verder te ontwikkelen en investeringen aan te trekken. Dat leidde tot de oprichting van ons bedrijf Pleco Therapeutics” aldus Ivo.

Removing cancer-promoting metals

In its drug research, Pleco Therapeutics initially focuses on acute myeloid leukaemia (AML). This rare form of blood cancer develops rapidly and is life-threatening if no treatment is started. In the Netherlands, approximately 700 people are diagnosed with AML every year. And only 30% are still alive five years after this diagnosis. Pleco Therapeutics develops medicines that tackle not only the cancer but also its underlying cause. “Over the course of their lives, people are exposed to metals. These metals accumulate in our bodies. When they reach a certain concentration, this can lead to disease. For a number of diseases, including AML, a clear link can be established between metals measured in the blood and the course of the disease. The medicines we develop remove these metals from the micro-environment of leukaemia cells. With this technology, we have found a way to make existing chemotherapy more effective, but also to tackle the cancer itself. The first results are promising and are expected to be shared later this year,” Ivo explains.

Looking for ways to increase the financial possibilities

“Pleco Therapeutics holds a licence on the invention of the academic centre in Houston. This means that we may develop the technology worldwide, but also that we have to arrange the financing,” says Ivo. To increase the organisation’s financial possibilities, Ivo went looking for investors, which ultimately also led to contact with Real1ze. “I was approached by Bas Krekelberg, director of Real1ze. There was an immediate click during the conversation. At that time, we were not yet thinking about funding in the Netherlands; we were working on other tracks. But that did become interesting when, in our financing round, we were able to conclude an agreement with the Belgian company Hyloris Pharmaceuticals. They wanted to invest in our project on the condition that we obtained additional financing. That immediately raised the question for us of how we could achieve that in the short term. I remembered the good conversation with Bas, got in touch again, and together we came to the conclusion that the Innovation Credit offered a very interesting opportunity,” says Ivo.

Innovation Credit brings financial support of 5 million

The Innovation Credit is available for innovative development projects with excellent market prospects, such as the Pleco Therapeutics project. That was not the only reason why this particular scheme proved interesting. “The size of the amount we could apply for fitted well as co-funding alongside the Hyloris financing. In addition, the Innovation Credit is intended for companies that cannot, or can only with difficulty, secure financing. That was also the case for us, because we are developing a new concept. And the timing was right as well,” says Ivo. The Innovation Credit is made available by the government every year and the application round starts on 1 January. “Together with Real1ze, we submitted our application on 1 January 2022. After a few months of suspense, we received the long-awaited news from RVO in May. Funding of 5 million had been awarded. I immediately called Real1ze to share this good news with them,” Ivo continues. The Innovation Credit is part of a total financing round of no less than 17.3 million.

Real1ze’s expertise is absolutely indispensable

“We were in contact with several grant consultancies, but Real1ze stood out immediately. That has mainly to do with the personal approach. In addition, they understand our market. They share their experiences from other projects and show what did or did not go well there. That inspires confidence,” says Ivo. “Real1ze’s expertise is absolutely indispensable. First of all, they know better than anyone how to make things understandable for ‘the other side’, such as the RVO assessors. We are a group of scientists who have to explain to a civil service what we do. Real1ze did that very well. Something we would never have managed without Real1ze is the financial model. It is quite complex. You can hardly do it yourself without a lot going wrong. For that, you really need the experience and the strategic thinkers of Real1ze,” Ivo indicates. “I can wholeheartedly recommend working with Real1ze. By the way, I would have done so even if we had not received the Innovation Credit. You remain dependent on the assessors, but working with Real1ze increases the chances enormously,” says Ivo.

There will definitely be a sequel

It will not stop at this one time. Together with Real1ze, Pleco Therapeutics is looking at another interesting grant instrument for which there are opportunities. In addition, a further application for the Innovation Credit is not ruled out. “After this successful start, our collaboration will certainly continue,” Ivo concludes.

Previous Post
Microsure receives over € 100,000 in additional WBSO benefit